The Influence Of Rosuvastatin Combining Ezetimibe On Blood Lipid, Carotid Atherosclerostic Plaque,hs-CRP In Patients With Cerebral Infarction

Objective: More and more scale clinical studies have confirmed that hyperlipidemiaas an independent risk factor for coronary atherosclerotic heart disease andcerebrovascular disease. In this study,we compared two different lipid-lowering recipes fortheir effect and safety in controlling blood lipid, in order to find an optimal lipid controltherapy for secondary prevention of stroke patients.Material and Methods：Inpatients with cerebral infarction patients in the neurologydepartment of our hospital from June1st,2012to June30st,2013were selected for thestudy, these patients are all with carotid atherosclerotic plaque and hyperlipemia（TC>5.69mmol/L，LDL-C>3.10mmol/L），98subjects were classified into two groups,all subjects were not used statins and lipid-lowering medication before in the group, thesepatients have no dysfunction of liver and kidney, without acute severe infection, withoutsurgery and trauma history in the three months,without metabolic and endocrine systemdisease, without malignant tumor history, two groups of patients with sex, age andgeneral clinical data comparison difference has no statistical significance (P>0.05),respectively.All subjects were given standard preventive medications after admission,including aspirin, antihypertensive drugs，the control group was only given rosuvastatin，the observation group was given rosuvastatin combining ezetimibe， the medicationperiod was6months，empty-stomach blood level of LDL-C,HDL-C,TG,TC,ALT,AST,CK,Apo-B, hs-CRP were tested in outpatients at the12thand24thweek, and measure carotidartery atheromatous plaque in a transverse maximum,carotid artery intima-media thicknesson line24weeks in our ultrasonic room. Record the primary end point events and asecondary end point events after the drug therapy.Results： TC, TG, LDL-C and Apo-B levels of two groups after treatment were significantly lower than before treatment (P<0.05)，LDL-C and Apo-B of observationgroup was significantly lower than those of the control group (P<0.05). Hs-CRP levels oftwo groups after treatment were reduced significantly than before treatment (P<0.05), twogroups was no statistical significance (P>0.05)， carotid atherosclerostic plaque ofobservation group after treatment were reduced significantly than before treatment(P<0.05), the control group was no significant change before and aftertreatment(P>0.05),Adverse effects rate of two groups was no statistical significance(P>0.05).Conclusion:1.blood lipid level of two groups after treatment were significantly lower than beforetreatment, but Rosuvastatin combining ezetimibe can effectively reduce LDL-C and TC.2.Rosuvastatin combining ezetimibe may have certain stability function on carotidatherosclerotic plaques.3. Elevated TC、LDL-C levels may promote the formation of carotid plaques.4. Adverse effects rate of two groups was no statistical significance (P>0.05).